[키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval benefit Casirivimab convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Emergency use Evidence fatal COVID-19 Globulin high risk hyperimmune hyperimmune globulin immune immune system Infection Japan lack Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 monoclonal neutralizing monoclonal antibodies other treatment pandemic Passive Patient patient groups performed Prevent Regulatory required Research respiratory respiratory infections SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe respiratory infections Therapies therapy treat Treatment United Kingdom
[DOI] 10.1182/hematology.2021000299 PMC 바로가기 [Article Type] Review